Findings from large, late-stage clinical trials in melanoma, nonâ€“small cell lung cancer, and several hematologic malignances are expected to rank among the most clinically significant research findings presented at the 2015 American Society of Clinical Oncology Annual Meeting.
Findings from large, late-stage clinical trials in melanoma, non—small cell lung cancer (NSCLC), and several hematologic malignances are expected to rank among the most clinically significant research findings presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, according to industry analysts.
In keeping with the trend over the past several years, immunotherapies will attract much interest at this year’s conference, which opens Friday in Chicago. The checkpoint inhibitors nivolumab (Opdivo) and ipilimumab (Yervoy) are generating the most attention in this class of therapy but emerging monoclonal antibodies with immunogenic qualities also register among the highlights.
With more than 5000 abstracts presented during the conference, pharmaceutical industry analysts have been combing the data for clues that will affect the financial fortunes of the companies developing the drugs. One biotech saw its stock plunge after ASCO took the wraps off the abstracts in mid-May and other companies are likely to find their market positions enhanced or damaged when the data are fully presented. For late-breaking abstracts, data will be released shortly before the presentation.
Kantar’s Top Abstracts List
Experts from Kantar Health, a market research firm based in New York City, have identified 10 abstracts involving nine different agents for its Top Presentations of Interest to be presented at this year’s conference (https://goo.gl/eLXPja). All of the entries on the list concern phase III clinical trial data. Here is a snapshot of that research, with the corresponding abstract numbers:
Emerging Agents Showcased
While Puma Biotechnology’s experience provides a dramatic example of the ways in which ASCO abstracts can affect a company’s prospects in the marketplace, the conference offers an opportunity for pharmaceutical developers throughout the world to shine a spotlight on their research programs.
In addition to the late-stage clinical trial findings that Kantar cited, there are many studies that are expected to help physicians determine optimal uses for established and emerging compounds. Here are some of the agents that oncology thought leaders, analysts, and the companies themselves consider noteworthy:
ASCO abstracts are available at https://iplanner.asco.org/am2015/AM2015.aspx. For breaking news and updates, visit www.OncLive.com.